Indo Borax Expects FY27 Revenue Of ₹250–260 Crore Supported By ₹50 Crore Capex

Market snapshot: Indo Borax & Chemicals Limited has structured an aggressive business plan for FY27, targeting revenue of ₹250 crore to ₹260 crore. Backed by a capital expenditure outlay of ₹50 crore and a target to scale its agricultural micronutrient sales volume to 1,500 tonnes, the company is positioning itself to capture a larger share of the domestic boron derivatives market.

Data Snapshot

• Targeted FY27 revenue is set between ₹250 crore and ₹260 crore, backed by 20% EBITDA margin guidance.
• The company aims to achieve 1,500 tonnes in DOT sales volume for the year.
• A capital expenditure plan of ₹50 crore is outlined for capacity expansion in Boron Oxide and Boric Acid.
• Consolidated net profit for Q1 FY27 grew 59.31% YoY to ₹16.25 crore from ₹10.20 crore.

What's Changed

• Revenue Growth Trajectory: Target of ₹250–260 crore marks an expansion of ≈16% to 21% YoY (derived: ₹250–260 crore vs ₹215 crore in FY26).
• DOT Volume Expansion: Moving target of 1,500 tonnes for DOT is ≈67% YoY higher (derived: 1,500 tonnes vs 900 tonnes in FY26).
• Capex Acceleration: Committing ₹50 crore over 2-3 years, with ₹20 crore allocated for Boron Oxide and ₹20–25 crore for Boric Acid capacity enhancements.

Key Takeaways

• Import Substitution Focus: Scaling DOT volumes directly addresses a domestic market that currently relies heavily on imported supply.
• Conservative Margin Outlook: Though Q1 FY27 EBITDA margins hit 28.1%, the full-year target of 20% is conservatively guided to handle commodity raw material volatility.
• Balance Sheet Prudence: The company continues to maintain its zero-debt status, meaning the planned ₹50 crore capex will be funded entirely via internal accruals.

SAHI Perspective

Indo Borax's decision to self-fund its capacity expansion while maintaining its debt-free status demonstrates exceptional capital allocation discipline. While the guidance for a 20% EBITDA margin is significantly lower than the 28.1% recorded in Q1 FY27, this represents an appropriate conservative posture given shipping and raw-material import lead times. The push to more than double DOT volumes over consecutive periods presents a high-margin product mix upgrade that could bolster long-term cash generation.

Market Implications

The specialty chemicals space in India is undergoing structured import-substitution. Indo Borax's expansion into boron derivatives can significantly improve its market share. Additionally, diversifying technical grade boric acid capacity into specialized downstream products will insulate it from commodity-like pricing cycles over the next 2-3 years.

Trading Signals

Market Bias: Bullish

Firm guidance of ₹250–260 crore for FY27 combined with an internal accrual-funded ₹50 crore capex plan signals robust financial health. High-volume growth target of 1,500 tonnes in the specialized DOT segment acts as a key valuation driver.

Overweight: Specialty Chemicals, Agriculture Inputs

Trigger Factors:

• Raw material price volatility of imported boron ore.
• Execution timelines of the Boron Oxide capacity expansion.
• Quarterly volume updates of DOT sales.

Time Horizon: Medium-term (3-12 months)

Industry Context

The domestic Indian boric acid market has historically been constrained by limited local production of advanced downstream derivatives. By operating as the country's sole FDA and BIS licensed producer of IP-grade boric acid and expanding disodium octaborate tetrahydrate capacity, Indo Borax holds an insulated position inside a high-barrier chemical market.

Key Risks to Watch

• Dependence on imported raw materials which carries a lead time of three-to-four months.
• Potential execution delays in setting up the proposed Boron Oxide and Boric Acid capacities.
• Forex and shipping cost fluctuations that could compress guided 20% margins.

Recent Developments

Indo Borax approved the acquisition of a 64.26% stake in Kronox Lab Sciences for ₹246.12 crore in August 2026, marking a pivot toward inorganic expansion into the high-purity specialty chemicals space. Furthermore, India Ratings assigned a stable 'IND BBB+' rating to the company's bank loan facilities on July 23, 2026.

Closing Insight

Indo Borax's FY27 guidance is a masterclass in realistic goal-setting. Balancing inorganic expansions with a robust, debt-free organic capex trajectory makes it one of the most fundamentally secure small-cap specialty chemical plays in the Indian market today.

High Performance Trading with SAHI.